Please login to the form below

Not currently logged in
Email:
Password:

Sanofi to donate 60m doses of bird flu vaccine

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has announced that it will donate 60m doses of its H5N1 vaccine to the World Health Organisation
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has announced that it will donate 60m doses of its H5N1 vaccine to the World Health Organisation (WHO).

In 2007, the first licence in the US for an avian influenza vaccine for humans was issued to Sanofi Pasteur by the US Food and Drugs Administration (FDA). Since 2004, the company has produced millions of doses of H5N1 vaccine.

"The H5N1 virus is currently circulating in some of the poorest regions of the world and an outbreak of pandemic influenza would most likely hit populations living in areas with limited access to vaccines," said Wayne Pisano, president and chief executive officer of Sanofi Pasteur.

"This donation of H5N1 vaccine aims to address the needs of those most vulnerable populations."

In a press release issued in October 2007, WHO said that with improvements in manufacturing technology, experts anticipated a global production capacity of 4.5bn pandemic immunisation courses per year by 2010.

Based on its internal data, Sanofi Pasteur claims to be lead producer of influenza vaccines, supplying an estimated 40 per cent of the world influenza vaccine market.

17th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics